Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Rhinomed.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX health stocks: Shares in cancer-fighting company Noxopharm edge higher following its full-year results
Health & Biotech
Rhinomed shares gain another 20pc, after 1 million Rhinoswab order from the Victorian government
News
August ASX Winners Column: Reporting season failed to get investors excited, but coal, lithium and COVID battlers did
News
Closing Bell: ASX closes slightly lower, still notches up weekly gain
News
ASX Small Cap Lunch Wrap: Who’s trying not to blink today?
News
10 at 10: These ASX stocks are doing the best amidst the rough markets this morning
Health & Biotech
Check up: Rhinomed (ASX:RNO) soars with NSW COVID contract, and genetic testing fails to impress
Health & Biotech
ScoPo’s Powerplays: ‘Lots of money on sidelines waiting for pullbacks’, as all eyes are on earnings next week
News
Weekly ASX small cap wrap: Market maintains upward momentum
News
Closing Bell: ASX cruises to another record high ahead of US inflation data
News
ASX Small Cap Lunch Wrap: Who’s ready for a US$1 trillion infrastructure bill this morning?
Health & Biotech
ASX health stocks: Rhinomed rockets 80% after securing first government purchase for COVID-19 Rhinoswabs
Health & Biotech
Rhinomed positioned for growth in billion-dollar nasal tech market, as share price rockets 40pc in a month
Experts
ScoPo’s powerplays: Healthcare hit by ‘Covid exit trade’, but opportunities remain
News
Last Orders: What you might have missed on the ASX today
Health & Biotech
Health Kick Podcast: Investors smell success in Rhinomed’s flu and coronavirus nasal swab technology
News
